Semaglutide Week-by-Week Timeline: The STEP 1 Trajectory to 14.9% at 68 Weeks

The most useful thing to know about semaglutide before starting a research protocol is that the timeline is not short and it is not linear. STEP 1, the pivotal obesity trial published in the New England Journal of Medicine in 2021, measured its primary outcome at 68 weeks, a year and a half of dosing, not at one month or three. ^[1] That choice of endpoint tells you something important: the compound's effect compounds over a long arc, and the trial designers built their measurement schedule around that shape rather than around an early snapshot.

This is a phase-by-phase look at what the trial data and the underlying pharmacology suggest to expect: when the starting dose gives way to something more, when the titration schedule reaches its target, when the steepest weight change tends to show up, and what the 68-week figure actually represents. Everything here reports published clinical findings; none of it is medical advice, and the semaglutide discussed here is a research compound, not the approved pharmaceutical product dispensed as Ozempic or Wegovy.

The semaglutide timeline at a glance

The rest of this guide unpacks each phase: what drives it, what the trial reported, and why the protocol is built the way it is.

What to expect in weeks 1 to 4: the starting dose

The first month on a semaglutide research protocol is deliberately quiet. STEP 1's dosing schedule opens at 0.25 mg once weekly for four weeks, a dose the trial protocol describes as a priming step rather than an effective maintenance dose. ^[1] The purpose of this starting dose is tolerability, not results: it gives the gastrointestinal system time to adjust to GLP-1 receptor activation before the dose climbs any further.

Because of this, weeks 1 to 4 are not a fair test of what the compound can do. Some people notice an early softening of appetite as GLP-1 receptor activation begins to affect appetite circuits and gastric emptying, but the dose is intentionally the lowest it will ever be during the protocol. ^[2] Reading this month as a verdict is the single most common way people misjudge the timeline before it has even started.

If gastrointestinal effects appear at all, this early window and each subsequent dose increase are where the trial literature reports them clustering, easing once a given dose level is held steady for a few weeks. ^[1] The mechanism is the same one that eventually drives the weight-loss effect: slowed gastric emptying and reduced appetite signaling, most noticeable while exposure is actively changing.

When does semaglutide start working, and why it builds slowly

Appetite and weight effects do not switch on; they build alongside rising plasma concentration and rising dose, two things that happen in tandem for the first several months of a standard protocol. Semaglutide's action on the GLP-1 receptor touches appetite regulation, gastric emptying, and glucose-dependent insulin secretion, and the strength of that signal scales with how much of the compound is actually circulating. ^[2]

The pharmacology behind the slow build is a roughly 7-day half-life. ^[2] On a weekly dosing schedule, each dose layers onto residual exposure from the prior one, so concentration climbs stepwise across several weeks at any fixed dose before leveling off. Because the STEP 1 schedule also raises the dose itself every four weeks during titration, plasma levels are almost never flat during the first several months: they are climbing toward a moving target. Only once the 2.4 mg maintenance dose is reached and held constant, without a further increase, do levels have room to fully settle.

This is the honest answer to "how long does semaglutide take to work." Some signal appears early, but the trial's own reported effect is a months-long trajectory, built from a rising dose meeting a rising plasma level, not a first-month verdict.

Weeks 4 to 16: the titration schedule

Once the starting month ends, the STEP 1 schedule begins raising the dose every four weeks, holding each level long enough to assess tolerability before the next step. ^[1] That schedule runs through three more step-ups after the initial four-week starting period, arriving at the 2.4 mg maintenance dose at roughly week 17.

Two things are happening at once during this stretch. First, each new dose has to climb toward its own local steady state before the next increase arrives, so plasma exposure is in near-constant motion. Second, weight loss that was minimal in the first month becomes gradually more apparent as the compounding effect of successive dose increases builds on itself. The trial's stepwise design exists specifically to make this phase tolerable, and rushing it, by skipping steps or escalating faster than the schedule allows, is, per the trial's own tolerability data, one of the more common reasons a protocol is abandoned before the results phase even begins. ^[1] The full dosing structure, including the units-to-mg conversion at reconstitution, is covered in the semaglutide dosing and titration guide.

Weeks 17 to 52: reaching the target dose and the steepest change

Once the 2.4 mg maintenance dose is reached, around week 17, plasma levels still need several more weeks to fully settle given the roughly 7-day half-life. ^[2] From that point forward, with no further dose increases in the way, the compound is finally delivering its full, stable intended exposure, and this is where the trial's steepest mean weight change tends to concentrate.

This is also where the responder pattern becomes clear rather than theoretical. STEP 1 did not report a good average sitting on top of a wide, inconsistent spread. Among participants on the 2.4 mg dose, 86.4% reached at least 5% weight loss, 69.1% reached at least 10%, and 50.5% reached at least 15%, meaning half the trial population crossed a threshold once considered an ambitious ceiling for pharmacotherapy alone. ^[1] For most people running a full-length protocol, the stretch from roughly month five through month twelve is where the visible transformation happens, even though the headline number is reported at the very end.

The 68-week STEP 1 endpoint: what 14.9% represents

The 68-week timepoint is the anchor of everything known about semaglutide's obesity-trial efficacy, so it is worth being precise about what it means. STEP 1 enrolled adults with obesity or overweight without diabetes and measured mean body-weight change from baseline at 68 weeks on the 2.4 mg dose. ^[1] The treatment group's mean loss of 14.9% dwarfed the 2.4% recorded on placebo. ^[1]

"Mean" is the operative word. Individual responses scattered around that average, and the broader STEP program reported the result varies by population and design: STEP 2, in adults with type 2 diabetes, reached 9.6% at the same 2.4 mg dose, a smaller magnitude typical of that harder-to-treat population. ^[3] STEP 3, which paired semaglutide with intensive behavioral therapy, reached 16.0%, the highest figure in the program. ^[4] The table below places the program's timepoints side by side.

That spread across four trials is the honest picture: the 14.9% figure most commonly quoted is STEP 1's specific population and design, not a universal constant, and the number moves depending on comorbidity and whether behavioral support runs alongside the compound.

Semaglutide before and after: what changes month by month

The "before and after" question, one month, two months, three months, six months, is one of the most common ways people search for this compound, and it deserves a direct answer even though STEP 1's official endpoints were measured at prespecified trial timepoints, not at each individual month. The approximate shape below is an illustrative interpolation of the reported trajectory and titration schedule, not a set of official month-by-month figures published by STEP 1.

The pattern that holds regardless of the exact numbers is direction and shape: slow in the first one to two months while the dose is still low, building through months three to five as titration completes, and then accounting for most of the visible change from roughly month six through month twelve, before the rate of loss moderates on the way to the 68-week figure. Comparing a one-month or two-month photo against the 14.9% headline number is comparing two different points on a curve that was never designed to be read early.

Semaglutide weight-loss dosage chart

A related, frequently searched question is how the dose itself changes the outcome, since semaglutide has been studied across several doses and formulations, not just the 2.4 mg weekly injection most associated with STEP 1.

Two things stand out in that chart. The dose-response relationship is orderly: within a comparable population, a higher dose of the same molecule produces more mean weight loss, which is the pattern you would expect from a real, scalable mechanism rather than a coincidental result. And the oral tablet, at a much higher milligram dose to compensate for lower gut absorption, can match or exceed the injectable dose's result, evidence that the route of administration is a delivery detail layered on top of the same underlying GLP-1 mechanism. ^[6]

Why the timeline looks the way it does: the half-life rationale

The entire shape of this timeline, a quiet starting dose, a four-month titration, a settling period, then a longer accelerating stretch, traces back to one pharmacological fact: semaglutide's roughly 7-day half-life. ^[2] Amino-acid substitutions that resist DPP-4 breakdown, paired with a fatty-diacid side chain that binds the molecule to circulating albumin, extend its functional half-life from the minutes native GLP-1 lasts to roughly a week. ^[2] That extended half-life does three things that define the shape of the timeline:

• It enables once-weekly dosing. A roughly 7-day half-life keeps plasma concentration in an effective range across a full week, so a single weekly subcutaneous dose maintains steady exposure between injections. ^[2]
• It creates the multi-month ramp. Because each dose overlaps with residual exposure from prior doses, and because the dose itself keeps rising during titration, levels are effectively climbing for months rather than settling quickly.
• It buffers a missed dose within reason. A single delayed or skipped week lowers but does not eliminate exposure, because clearance is slow. The flip side is that after stopping, it takes roughly five weeks for the compound to clear substantially.

Does semaglutide plateau, and how long does the effect last

Because the STEP 1 curve had not clearly flattened by the 68-week endpoint, a reasonable question is how long the loss continues beyond that point, and what happens if dosing stops. ^[1] STEP 4 answers the second question directly. All participants ran in for 20 weeks on semaglutide, reaching a mean of 10.6% loss, then were randomized to either continue or switch to placebo. Those who continued kept losing, reaching roughly 17.4% total loss by week 68. Those switched to placebo regained a substantial share of the weight they had lost. ^[5]

That result answers "how long can you take it" and "how long should you take it" in the way the trial evidence actually supports: the effect is maintained by continued dosing, not banked permanently after a fixed course, and the timeline described throughout this guide describes an active protocol, not a set duration after which the result locks in place.

How long has semaglutide been around

Semaglutide is not a new molecule. The FDA first approved it in December 2017 as Ozempic, for type 2 diabetes, at doses in a lower glycemic-control range. ^[7] STEP 1, the trial that established its weight-management profile at the higher 2.4 mg dose, published in 2021, the same year the FDA approved Wegovy specifically for chronic weight management. ^[7] That means the timeline in this guide describes a compound with roughly nine years of regulatory and real-world history behind it as of this writing, longer than either of the newer multi-receptor agonists it is often compared against.

Common ways people misread the semaglutide timeline

• Judging the starting dose as the verdict. The 0.25 mg dose is a priming step the trial did not expect to produce meaningful loss on its own; judging the compound from this month alone is the single most common error. ^[1]
• Expecting linear loss across 68 weeks. The trajectory is phased: a four-month titration, a settling period once the target dose is reached, then an accelerating middle stretch, then a slowing tail. A flat early period followed by a longer period of steady change is the expected shape.
• Rushing titration to reach the target dose sooner. The stepwise schedule exists to manage gastrointestinal tolerability, and compressing it works against the very design that made the 2.4 mg dose tolerable enough to reach in the trial. ^[1]
• Comparing an in-progress protocol to the 68-week endpoint figure. A protocol still mid-titration at 8 or 12 weeks should not be measured against a number the trial recorded well over a year in.
• Treating the STEP 1 result as a fixed, permanent outcome. STEP 4 showed the effect depends on continued dosing, not a course with a banked result. ^[5]

Realistic expectations, phase by phase

The timeline is not a promise of any individual outcome. The 14.9% figure is a trial mean on the 2.4 mg dose, and individual responses vary, with STEP 2 and STEP 3 showing the same molecule producing meaningfully different mean results depending on population and support. ^{[3] [4]} But the phase structure is reliable enough to plan around: a quiet, tolerability-focused start; a titration stretch of roughly 16 weeks; a settling period once the 2.4 mg dose is held steady; an accelerating middle stretch where most of the visible change tends to concentrate; and a slowing but still-active tail toward the 68-week endpoint. Every phase maps to a mechanism: a deliberately low starting exposure, a rising dose, a rising and then stabilizing plasma concentration, and the compounding effect of a fully titrated maintenance dose sustained over more than a year.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies of the semaglutide molecule, including the FDA-approved products Ozempic and Wegovy; cross-timepoint and cross-dose comparisons are drawn from separate trials, not head-to-head studies. The semaglutide discussed here is a research compound and is not intended for human use.